Compare NVEC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | AURA |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.4M | 419.5M |
| IPO Year | 1995 | 2021 |
| Metric | NVEC | AURA |
|---|---|---|
| Price | $85.74 | $9.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 58.7K | ★ 337.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.12 | N/A |
| Revenue | ★ $25,874,694.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $57.21 | $4.73 |
| 52 Week High | $88.86 | $8.49 |
| Indicator | NVEC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 62.81 | 76.92 |
| Support Level | $64.17 | $6.00 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 4.23 | 0.50 |
| MACD | 0.20 | 0.12 |
| Stochastic Oscillator | 76.48 | 83.02 |
NVE Corp develops and sells devices that use spintronics, a nanotechnology that relies on electron spin. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.